How to Maximize Weight Loss on GLP-1 Therapy with Supporting Peptides

GLP-1 medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — produce significant weight loss in the majority of patients who take them. They also have real limitations that patients and clinicians do not always discuss honestly. A meaningful portion of the weight lost on GLP-1 therapy is lean mass rather than fat. Side effects are common and sometimes lead patients to discontinue therapy before reaching their goals. And weight regain after stopping therapy is the rule rather than the exception unless durable changes have been made.

Supporting peptides and complementary protocols can address several of these limitations. Used appropriately and under physician supervision, they can preserve lean mass during weight loss, counter common GLP-1 side effects, support recovery and energy during caloric restriction, and contribute to better long-term outcomes.

This article walks through how to think about GLP-1 therapy as part of a larger protocol rather than as a standalone intervention. Nothing in this article is medical advice for an individual patient — every protocol should be designed by a physician who knows your specific medical picture — but the framework is useful for understanding what a thorough GLP-1 program actually looks like. Our Metabolic Reset program is structured around exactly this kind of comprehensive approach.

What GLP-1 therapy does well

GLP-1 receptor agonists work through several mechanisms. They mimic the action of glucagon-like peptide-1, a gut hormone released after meals. They enhance glucose-dependent insulin secretion, improving blood sugar control. They slow gastric emptying, increasing satiety and reducing overall caloric intake. They act on appetite centers in the brain, reducing the drive to eat and changing the relationship many patients have with food.

The clinical results in trials are substantial. Semaglutide at 2.4 mg weekly produces approximately 15 percent average body weight loss at 68 weeks. Tirzepatide at 15 mg weekly produces approximately 21 percent average body weight loss at 72 weeks. For many patients, these are larger weight loss outcomes than they have achieved with any prior intervention.

The metabolic benefits extend beyond weight. Improvements in HbA1c, lipid profiles, blood pressure, and inflammatory markers are well-documented in the trial data. Cardiovascular outcome studies have shown reductions in major adverse cardiovascular events in appropriate populations.

This is what GLP-1 therapy does well, and it is why these medications have become as widely used as they have. Our medical weight loss service is built around them as a core offering.

What GLP-1 therapy doesn’t address — and why supporting protocols matter

The limitations of GLP-1 therapy are equally real and often glossed over in patient marketing.

Lean mass loss. Studies of GLP-1 therapy consistently show that 25 to 40 percent of the weight lost is lean mass rather than fat. The mechanism is straightforward — significant caloric restriction without adequate protein intake and resistance training produces muscle loss regardless of the medication driving the caloric restriction. For patients in their 40s, 50s, and beyond, muscle loss is a serious long-term concern. Sarcopenia accelerates aging, increases fall risk, worsens metabolic health, and is difficult to reverse later.

Side effects during titration. Nausea, decreased appetite, constipation, diarrhea, occasional vomiting, and fatigue are common during dose escalation. For some patients these are mild and resolve. For others they are significant enough to interfere with daily life or to cause discontinuation of therapy before reaching effective doses.

Energy and recovery during caloric restriction. Patients on GLP-1 therapy are often in a substantial caloric deficit. This can affect energy, training capacity, sleep quality, and recovery from physical activity. Without supportive interventions, the caloric deficit can become counterproductive over time.

Skin and connective tissue changes. Rapid weight loss is associated with skin changes — what some patients describe as “Ozempic face” or sagging in other areas. The underlying issue is partly mechanical (less subcutaneous tissue) and partly a reduction in collagen turnover during caloric restriction.

Plateau and adaptation. Some patients experience weight loss plateaus despite consistent medication adherence. Metabolic adaptation, declining lean mass, and reduced energy expenditure all contribute.

Each of these limitations has a potential solution. None requires abandoning GLP-1 therapy. All can be addressed through supporting protocols designed by a clinician familiar with the category.

Supporting peptides that complement GLP-1 therapy

Several peptides can be considered as part of a comprehensive GLP-1 protocol depending on individual clinical picture and goals. The decision to include any specific peptide should be made by a physician based on labs, medical history, and treatment goals — not based on a general protocol applied to every patient.

Growth hormone-supporting peptides

Peptides such as sermorelin, ipamorelin, and CJC-1295 stimulate the pituitary to release endogenous growth hormone in its natural pulsatile pattern. They are not growth hormone, and they do not produce supraphysiologic effects. They can support lean mass retention and recovery capacity in patients in caloric restriction, which is directly relevant to the lean mass loss problem in GLP-1 therapy.

For appropriate patients — particularly adults in their 40s and 50s with documented or suspected age-related decline in GH pulsatility — these peptides paired with adequate protein intake and resistance training can meaningfully shift the body composition of the weight loss. Less lean mass loss, more fat loss, for the same total weight change. Our longevity and performance service is the clinical home for this category.

Monitoring is required. IGF-1 levels should be tracked to ensure response stays within physiologic ranges. Contraindications include active malignancy and other specific conditions that should be ruled out before starting.

BPC-157 for GI symptoms and gut support

BPC-157 is a peptide derived from a protein in human gastric juice. It has substantial preclinical evidence for gut-protective effects and is used clinically for gut barrier function, GI inflammation, and recovery from GI distress.

For patients struggling with GLP-1 side effects — particularly persistent nausea, constipation, or GI discomfort that has not resolved with dose adjustment — a course of oral BPC-157 protocol can sometimes improve tolerance and allow continued therapy at effective doses. The human evidence is more limited than the preclinical, but the safety profile in clinical use has been favorable, and the mechanism aligns with the problem.

Thymosin alpha-1 for immune support

Patients in significant caloric deficit sometimes experience reduced immune function — more frequent minor illnesses, slower recovery from infections, generalized resilience changes. For appropriate patients, immune-modulating peptides like thymosin alpha-1 can support immune function during the weight loss phase. Our immunity and inflammation service covers this use case in detail.

This is a smaller use case and not relevant to every patient on GLP-1 therapy, but for patients who notice immune changes during their protocol, it can be a relevant addition.

GHK-Cu for skin and connective tissue

GHK-Cu is a copper peptide with substantial dermatologic literature for collagen synthesis, wound healing, and skin quality. For patients concerned about skin changes during significant weight loss, GHK-Cu protocols can support collagen turnover and skin quality.

The evidence is strongest for the topical and injectable dermatologic uses. The systemic effects are still being characterized. For patients with specific skin and tissue concerns during weight loss, it is a reasonable addition to consider.

NAD+ therapy for energy and mitochondrial support

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism, mitochondrial function, and several longevity-associated pathways. Patients in significant caloric restriction sometimes report meaningful energy improvements with NAD+ IV therapy or subcutaneous NAD+ protocols.

The clinical evidence for NAD+ supplementation is still developing and patient response varies considerably. For appropriate patients who have plateaued on energy or recovery despite otherwise good protocol adherence, it can be a relevant addition. Our NAD+ and IV therapy service covers the delivery options.

The non-peptide pieces that matter most

Before adding any supporting peptide, the foundational pieces of a good GLP-1 protocol have to be in place. These are not optional, and no peptide will compensate for their absence.

Adequate protein intake. Patients on GLP-1 therapy should target approximately 1 gram of protein per pound of target body weight, distributed across the day. This is more than most patients eat by default and significantly more than most patients eat when their appetite has decreased on GLP-1 therapy. Without adequate protein, lean mass loss accelerates and outcomes deteriorate.

Resistance training. Two to four sessions per week of structured resistance training. Not cardio, not “movement” — actual resistance training that progressively challenges muscle. This is the single most important non-pharmacologic intervention for preserving lean mass during weight loss.

Sleep. Seven to nine hours of quality sleep. Sleep deprivation increases hunger, reduces satiety hormone function (the same hormones GLP-1 is trying to support), worsens insulin sensitivity, and impairs recovery from training. A protocol that does not address sleep is incomplete.

Hydration and electrolytes. GLP-1 therapy reduces fluid intake along with food intake. Patients commonly become dehydrated and electrolyte-depleted, which contributes to fatigue, headaches, and the constipation that is a frequent side effect. Deliberate hydration and electrolyte intake matters.

Lab monitoring. Comprehensive metabolic panel, lipid profile, HbA1c, fasting insulin, hs-CRP, and other relevant markers at baseline, 90 days, and 180 days. Body composition tracking with DEXA scans where available. Without measurement, you cannot tell whether the protocol is working in the ways that actually matter long-term. Our advanced labs service handles this monitoring as part of the program.

The protocol structure

A thorough GLP-1 protocol looks something like this in practice:

Baseline. Comprehensive consultation, comprehensive labs, body composition measurement, medical history review, goal setting. Selection between semaglutide and tirzepatide based on clinical picture.

Months 1–3. Initiation and titration of GLP-1 therapy. Dose escalation managed clinically based on response and tolerance. Establishment of foundational protocols — protein, training, sleep, hydration. Monthly physician check-ins. Supporting peptides added as clinically indicated based on individual response.

Months 4–6. Maintenance phase. Adjustments based on response. Repeat labs at 90 days. Body composition reassessment. Protocol refinement.

Beyond month 6. Decisions about ongoing therapy, dose adjustments, transition to maintenance, or eventual discontinuation. Comprehensive labs at 180 days. Long-term planning based on the trajectory.

This is what serious GLP-1 medicine looks like. It is not a once-weekly injection and a scale check. It is a multi-component protocol with ongoing clinical adjustment — and it is the structure behind our Metabolic Reset program.

What to ask your clinic

If you are starting GLP-1 therapy or already on it, the questions that distinguish a thorough clinic from a transactional one:

What labs are you running at baseline and at follow-up? If the answer is minimal, you are not getting the picture you need.

How do you decide between semaglutide and tirzepatide? If the answer is “whatever insurance covers” or “we only prescribe one,” that is a limitation worth knowing.

What is your protocol for managing side effects beyond dose adjustment? If the answer is “tough it out,” you have options the clinic is not offering.

How do you address lean mass loss during weight loss? If the answer does not include protein targets, resistance training discussion, and consideration of supporting protocols, lean mass is being lost without being addressed.

What does ongoing monitoring look like at 90 days, 180 days, and beyond? If the answer is “we refill the prescription,” you are not getting a clinical relationship.

About The Tide

The Tide is a peptide-focused medical clinic in Houston, Texas, located adjacent to the Texas Medical Center. Our medical weight loss service and Metabolic Reset program are six-month physician-designed GLP-1 protocols with baseline and follow-up biomarker panels, monthly check-ins, physician-managed titration, and supporting peptide protocols where clinically indicated. We prescribe both semaglutide and tirzepatide, sourced from vetted 503A and 503B compounding pharmacies or as FDA-approved products where appropriate. For deeper reading on individual peptides, see the full peptide library.